Pharmacogenetic factors affecting β-blocker metabolism and response

References

• Kd Ms K, Xu JQ, Deaths: AE. Final data for 2017. National Vital Stat Rep. 2019;68(9):1–77.
   Google Scholar
• Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018;(328):1–8.
   Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–177.
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127.
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776.
   Google Scholar
• Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism–clinical aspects. Pharmacol Ther. 1990;46(3):377–394.
   Google Scholar
• Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittel-Forschung. 2003;53(12):814–822.
   Google Scholar
• Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype–a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560.
   Google Scholar
• Lennard MS, Silas JH, Freestone S, et al. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1982 Aug;14(2):301–303.
   Google Scholar
• Lennard MS, Tucker GT, Silas JH, et al. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica. 1986 May;16(5):435–447.
   Google Scholar
• Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27(6):874–887.
   Google Scholar
• Distlerath LM, Guengerich FP. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc Natl Acad Sci U S A. 1984 Dec;81(23):7348–7352.
   Google Scholar
• Eichelbaum M, Baur MP, Dengler HJ, et al. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol. 1987 Apr;23(4):455–458.
   Google Scholar
• Nofziger C, Turner AJ, Sangkuhl K, et al. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020 Jan;107(1):154–170.
   Google Scholar
• Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 Aug;102(2):213–218.
   Google Scholar
• Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019 Jul;106(1):94–102.
   Google Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr;95(4):376–382.
   Google Scholar
• Goetz MP, Sangkuhl K, Guchelaar HJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018 May;103(5):770–777.
   Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127–134.
   Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul;102(1):37–44.
   Google Scholar
• Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb;83(2):234–242.
   Google Scholar
• Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020 Jan;13(1):116–124.
   Google Scholar
• Bae SH, Lee JK, Cho DY, et al. Simultaneous determination of metoprolol and its metabolites, alpha-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. J Sep Sci. 2014 Jun;37(11):1256–1264.
   Google Scholar
• PharmVar CYP2D6 gene page. Available from: https://www.pharmvar.org/gene/CYP2D6
   Google Scholar
• Batty JA, Hall AS, White HL, et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. Clin Pharmacol Ther. 2014 Mar;95(3):321–330.
   Google Scholar
• Fux R, Morike K, Prohmer AM, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005 Oct;78(4):378–387.
   Google Scholar
• Goryachkina K, Burbello A, Boldueva S, et al. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol. 2008 Dec;64(12):1163–1173.
   Google Scholar
• Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther. 2006 Feb;31(1):99–109.
   Google Scholar
• Jin SK, Chung HJ, Chung MW, et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther. 2008 Oct;33(5):567–573.
   Google Scholar
• Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004 Oct;76(4):302–312.
   Google Scholar
• Koytchev R, Alken RG, Vlahov V, et al. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol. 1998 Aug;54(6):469–474.
   Google Scholar
• Taguchi M, Nozawa T, Kameyama T, et al. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol. 2003 Sep;59(5–6):385–388.
   Google Scholar
• Terra SG, Pauly DF, Lee CR, et al. Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005 Mar;77(3):127–137.
   Google Scholar
• Sehrt D, Meineke I, Tzvetkov M, et al. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011 Jun;12(6):783–795.
   Google Scholar
• Blake CM, Kharasch ED, Schwab M, et al. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther. 2013 Sep;94(3):394–399.
   Google Scholar
• Bijl MJ, Visser LE, van Schaik RH, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009 Jan;85(1):45–50.
   Google Scholar
• Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. Jama. 1995 Nov 22–29;274(20):1611–1613.
   Google Scholar
• Johnson JA, Herring VL, Wolfe MS, et al. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther. 2000 Sep;294(3):1099–1105.
   Google Scholar
• Lai ML, Wang SL, Lai MD, et al. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1995 Sep;58(3):264–268.
   Google Scholar
• Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909–915.
   Google Scholar
• Nieminen T, Uusitalo H, Maenpaa J, et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol. 2005 Dec;61(11):811–819.
   Google Scholar
• Sowinski KM, Burlew BS. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy. 1997 Nov-Dec;17(6):1305–1310.
   Google Scholar
• Briciu C, Neag M, Muntean D, et al. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Clujul Med. 2015;88(2):208–213.
   Google Scholar
• Briciu C, Neag M, Muntean D, et al. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. J Clin Pharm Ther. 2014 Oct;39(5):535–540.
   Google Scholar
• Gheldiu AM, Popa A, Neag M, et al. Assessment of a potential pharmacokinetic interaction between nebivolol and bupropion in healthy volunteers. Pharmacology. 2016;98(3–4):190–198.
   Google Scholar
• Guo L, Wang S, Wan Z, et al. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects. J Clin Pharm Ther. 2020 Aug;45(4):632–637.
   Google Scholar
• Hu X, Lan T, Dai D, et al. Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828–1831.
   Google Scholar
• Lefebvre J, Poirier L, Poirier P, et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007 May;63(5):575–582.
   Google Scholar
• Vieira CP, Neves DV, Coelho EB, et al. Effect of CYP2D6 poor metabolizer phenotype on stereoselective nebivolol pharmacokinetics. Drug Metab Lett. 2018;12(1):68–70.
   Google Scholar
• Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 1995 May;57(5):518–524.
   Google Scholar
• Honda M, Ogura Y, Toyoda W, et al. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol Pharm Bull. 2006 Apr;29(4):772–778.
   Google Scholar
• Saito M, Kawana J, Ohno T, et al. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biol Pharm Bull. 2010;33(8):1378–1384.
   Google Scholar
• Takekuma Y, Takenaka T, Kiyokawa M, et al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol Pharm Bull. 2007 Mar;30(3):537–542.
   Google Scholar
• Hamadeh IS, Langaee TY, Dwivedi R, et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther. 2014 Aug;96(2):175–181.
   Google Scholar
• Gao X, Wang H, Chen H. Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol. Pharmacogenomics. 2017 Nov 2. DOI:10.2217/pgs-2017-0203
   Google Scholar
• Luzum JA, Sweet KM, Binkley PF, et al. CYP2D6 genetic variation and beta-blocker maintenance dose in patients with heart failure. Pharm Res. 2017 Aug;34(8):1615–1625.
   Google Scholar
• Lindamood C, Ortiz S, Shaw A, et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol. 2011 Apr;51(4):575–585.
   Google Scholar
• Bystolic (nebivolol) [package insert]. Irvine, CA: Allergan; 2017.
   Google Scholar
• Rau T, Dungen HD, Edelmann F, et al. Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther. 2012 Jul;92(1):21–28.
   Google Scholar
• Yuan H, Huang Z, Yang G, et al. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res. 2008 Nov-Dec;36(6):1354–1362.
   Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001–2007.
   Google Scholar
• White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003 Aug;5(4):463–468.
   Google Scholar
• Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004 Dec;76(6):536–544.
   Google Scholar
• Lymperopoulos A, French F. Pharmacogenomics of heart failure. In: Yan Q, editor. Pharmacogenomics in drug discovery and development. New York (NY): Springer New York; 2014. p. 245–257.
   Google Scholar
• Joseph SS, Lynham JA, Grace AA, et al. Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol. 2004 May;142(1):51–56.
   Google Scholar
• Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999 Apr 30;274(18):12670–12674.
   Google Scholar
• La Rosee K, Huntgeburth M, Rosenkranz S, et al. The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics. 2004 Nov;14(11):711–716.
   Google Scholar
• Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003 Oct;74(4):372–379.
   Google Scholar
• Petersen M, Andersen JT, Jimenez-Solem E, et al. Effect of the Arg389Gly beta(1)-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment. Clin Exp Pharmacol Physiol. 2012 Sep;39(9):779–785.
   Google Scholar
• de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005 Mar;15(3):137–142.
   Google Scholar
• Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003 Jul;74(1):44–52.
   Google Scholar
• Liu J, Liu ZQ, Yu BN, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006 Jul;80(1):23–32.
   Google Scholar
• Van Driest SLSL, Dietz H Impact of variants in ADRB1 and CYP2C9 on atenolol and losartan response in Marfan syndrome. Paper presented at: Pediatric Academic Societies 2017 Annual Meeting; 2017 May 6–9; San Francisco, CA; 2017.
   Google Scholar
• Beitelshees AL, Zineh I, Yarandi HN, et al. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J. 2006 May-Jun;6(3):174–178.
   Google Scholar
• Karlsson J, Lind L, Hallberg P, et al. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol. 2004 Jun;27(6):347–350.
   Google Scholar
• O’Shaughnessy KM, Fu B, Dickerson C, et al. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond). 2000 Sep;99(3):233–238.
   Google Scholar
• Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther. 2003 Apr;73(4):366–371.
   Google Scholar
• Pacanowski MA, Gong Y, Cooper-Dehoff RM, et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008 Dec;84(6):715–721.
   Google Scholar
• Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010 Feb;24(1):49–60.
   Google Scholar
• Wu D, Li G, Deng M, et al. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to beta-blocker therapy in hypertension. J Int Med Res. 2015 Jun;43(3):424–434.
   Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery diseaseThe International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290(21):2805–2816.
   Google Scholar
• Iwai C, Akita H, Kanazawa K, et al. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J. 2003 Jul;146(1):106–109.
   Google Scholar
• Baudhuin LM, Miller WL, Train L, et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol. 2010 Aug 1;106(3):402–408.
   Google Scholar
• Kim KM, Murray MD, Tu W, et al. Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur J Clin Pharmacol. 2012 Nov;68(11):1483–1491.
   Google Scholar
• O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. Jama. 2009 Apr 8;301(14):1439–1450.
   Google Scholar
• Fiuzat M, Neely ML, Starr AZ, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013 Mar;15(3):258–266.
   Google Scholar
• Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001 May 31;344(22):1659–1667.
   Google Scholar
• Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288–11293.
   Google Scholar
• Aleong RG, Sauer WH, Robertson AD, et al. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):137–143.
   Google Scholar
• Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15(3):324–333.
   Google Scholar
• Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009 Jul 28;54(5):432–444.
   Google Scholar
• Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007 Oct;154(4):624–631.
   Google Scholar
• Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014 Nov 27;371(22):2061–2071.
   Google Scholar
• Benavente OR, White CL, Pearce L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke. 2011 Apr;6(2):164–175.
   Google Scholar
• Magvanjav O, McDonough CW, Gong Y, et al. Pharmacogenetic associations of beta1-Adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke. 2017 May;48(5):1337–1343.
   Google Scholar
• Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995 Jul;13(1):25–33.
   Google Scholar
• Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414–9419.
   Google Scholar
• Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001 Oct 4;345(14):1030–1035.
   Google Scholar
• Troncoso R, Moraga F, Chiong M, et al. Gln(27)–>Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol. 2009 May;104(5):374–378.
   Google Scholar
• Huang J, Li C, Song Y, et al. ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to beta-blockers in patients with heart failure. Cell Discov. 2018;4:57.
   Google Scholar
• Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008 May;14(5):510–517.
   Google Scholar
• Premont RT, Koch WJ, Inglese J, et al. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J Biol Chem. 1994 Mar 4;269(9):6832–6841.
   Google Scholar
• Kurnik D, Cunningham AJ, Sofowora GG, et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics. 2009 Oct;10(10):1581–1587.
   Google Scholar
• Lobmeyer MT, Wang L, Zineh I, et al. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan;21(1):42–49.
   Google Scholar